Editor's note

This ExpertREACT article was originally published on 11 December 2012 as part of the VacZine Analytics series. Pipeline statuses, market positions and forecasts described reflect the state of knowledge at that date.

An industry navigating austerity

2012 was largely a quiet year for the global vaccine industry as companies battled the sustained impact of government austerity measures and pushed lifecycle management initiatives. In late October GSK reported approximately £2.5bn in vaccine sales, a 6% decline at constant exchange rates on the same period of 2011. Corporate activity was limited with one notable exception: a March 2012 joint venture agreement with Japan's Daiichi Sankyo to create the number one vaccines company in Japan. In meningococcal vaccines GSK gained US FDA approval for MenHibrix (Hib-MenCY-TT) in June 2012 and a limited ACIP recommendation for infants at increased risk. The quadrivalent Nimenrix was approved by the EMA in April 2012 with launches underway across Europe.

Sanofi Pasteur's undoubted highlight - or lowlight - of the year was the Phase IIb efficacy data from its live attenuated CYD-dengue vaccine in 4,002 children aged 4 to 11 in Thailand. The vaccine demonstrated antibody responses against all four dengue serotypes, but protection was only demonstrated against three of the four in the intent-to-treat analysis. This partial efficacy result generated significant debate about the pathway to broad dengue vaccine licensure.

GSK vaccine sales Q3 YTD
£2.5bn
Down 6% at constant exchange rates versus the equivalent period of 2011

Novartis ends the year strongly

Novartis Vaccines was the standout performer, ending 2012 with two new product approvals - one of which was expected to shape significant commercial newsflow into 2013. Bexsero, the first broad-coverage meningococcal B vaccine, had received European approval and its commercial adoption trajectory was closely watched by the industry. For 2013 GSK anticipated QIV influenza approval and further Phase III progress for MAGE-3 and herpes zoster candidates, while most major players prepared for what was expected to be a pivotal year for meningitis B vaccine market development.